Paratek Pharmaceuticals, Inc.
http://paratekpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Paratek Pharmaceuticals, Inc.
Finance Watch: Kenvue, Acelyrin Launch Biggest Biopharma IPOs Of 2023
Public Company Edition: J&J’s consumer health spinout Kenvue grossed $3.8bn in its public market debut and Acelyrin raised $540m in an upsized IPO. Also, Seres accessed $250m in new debt for Vowst commercialization while follow-on offerings raised $325m for ImmunoGen and $240m for Morphic.
In Saudi Arabia, A Vision Of Healthcare Spurs Growth
As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.
Hasten, Orbital Raise 2023’s Biggest Venture Capital Rounds Days Apart
Hasten brought in $315m, and Orbital garnered $270m, but while multiple venture firms have raised large new funds, Q1 saw the lowest amount of biopharma VC fundraising in a single quarter since 2019.
Morphic Shows Potential For An ‘Oral Entyvio’ With Phase IIa Data
MORF-057, addressing the same target as Takeda blockbuster Entyvio, shows efficacy and safety in ulcerative colitis. Various companies have sought an oral competitor to established biologics in UC.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Novacea, Inc.
- Transcept Pharmaceuticals, Inc.
- TransOral Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice